Genotype analysis of rotaviruses isolated from children during a phase III clinical trial with the hexavalent rotavirus vaccine in China
Wenqi Zou, Qingchuan Yu, Yan Liu, Qingliang Li, Hong Chen, Jiamei Gao, Chen Shi, Ying Wang, Wei Chen, Xuan Bai, Biao Yang, Jiuwei Zhang, Ben Dong, Bo Ruan, Liuyifan Zhou, Gelin Xu, Zhongyu Hu, Xiaoming Yang · 2023
Read Genotype analysis of rotaviruses isolated from children during a phase III clinical trial with the hexavalent rotavirus vaccine in China by Wenqi Zou, Qingchuan Yu, Yan Liu, Qingliang Li, Hong Chen, Jiamei Gao, Chen Shi, Ying Wang, Wei Chen, Xuan Bai, Biao Yang, Jiuwei Zhang, Ben Dong, Bo Ruan, Liuyifan Zhou, Gelin Xu, Zhongyu Hu, Xiaoming Yang (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10786658.txt.
Description
The oral hexavalent live human-bovine reassortant rotavirus vaccine (RV6) developed by Wuhan Institute of Biological Products Co., Ltd (WIBP) has finished a randomized, placebo-controlled phase III clinical trial in four provinces of China in 2021. The trail demonstrated that RV6 has a high vaccine efficacy against the prevalent strains and is safe for use in infants.
Catalog record
| CREATOR | Wenqi Zou, Qingchuan Yu, Yan Liu, Qingliang Li, Hong Chen, Jiamei Gao, Chen Shi, Ying Wang, Wei Chen, Xuan Bai, Biao Yang, Jiuwei Zhang, Ben Dong, Bo Ruan, Liuyifan Zhou, Gelin Xu, Zhongyu Hu, Xiaoming Yang |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |